Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections

Area of Science:

• Microbiology
• Infectious Diseases
• Biotechnology

Background:

• Antimicrobial resistance (AMR) poses a significant global health threat, leading to increased mortality from common infections.
• Pseudomonas aeruginosa is a prevalent cause of healthcare-associated infections, often exhibiting resistance to multiple antibiotics.
• Bacteriophage (phage) therapy is being explored as a viable alternative to conventional antibiotics.

Purpose of the Study:

• To review the biodiversity of sequenced Pseudomonas aeruginosa phages.
• To consolidate in vitro and in vivo data on phage therapy efficacy against P. aeruginosa.
• To identify challenges and limitations in implementing phage therapy.

Main Methods:

• Comprehensive literature search for studies on P. aeruginosa phages.
• Analysis of genomic data for phage biodiversity.
• Systematic review of in vitro and in vivo experimental results of phage therapy.

Main Results:

• Extensive data on the biodiversity of P. aeruginosa phages has been compiled.
• Numerous studies demonstrate the in vitro and in vivo efficacy of phage therapy against P. aeruginosa.
• Key challenges in phage therapy, including regulatory and practical hurdles, have been identified.

Conclusions:

• Phage therapy is a promising strategy against Pseudomonas aeruginosa infections, supported by extensive research.
• Understanding phage biodiversity is crucial for optimizing therapeutic applications.
• Addressing the identified hurdles is essential for the successful clinical implementation of phage therapy.